Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coenzyme Q10 for Acute Stanford Type A Aortic Dissection (Feasibility RCT)
ChiCTR2600123230Phase 4Not yet recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in aortic dissection comparing Coenzyme Q10 with Placebo (2 arms). Primary endpoint: 14-day all-cause mortality at Day 15. Planned start May 2026; status: not yet recruiting.
02
Drugs
coenzyme q10
03
Conditions
aortic dissection
Beyond the preview
Go deeper on ChiCTR2600123230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123230.